<DOC>
	<DOCNO>NCT02301936</DOCNO>
	<brief_summary>This study evaluate safety , tolerability , antiviral efficacy ledipasvir/sofosbuvir ( LDV/SOF ) fixed-dose combination ( FDC ) administer 12 24 week adults genotype 1 4 hepatitis C virus ( HCV ) infection sickle cell disease ( SCD ) .</brief_summary>
	<brief_title>Ledipasvir/Sofosbuvir Fixed-Dose Combination 12 24 Weeks Genotype 1 4 HCV Infected Adults With Sickle Cell Disease</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<mesh_term>Ledipasvir</mesh_term>
	<mesh_term>Ledipasvir , sofosbuvir drug combination</mesh_term>
	<criteria>Chronic genotype 1 4 infected patient sickle cell disease HCV RNA â‰¥ 1,000 IU/mL screen Cirrhosis determination transient elastography Screening laboratory value within define threshold Use two effective contraception method female childbearing potential sexually active male Pregnant nursing female Coinfection HIV hepatitis B virus ( HBV ) Current prior history clinical hepatic decompensation Hepatocellular carcinoma ( HCC ) malignancy ( exception certain resolve skin cancer ) History clinically significant illness medical disorder may interfere treatment , assessment compliance protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Sickle Cell Disease</keyword>
	<keyword>Gilead</keyword>
	<keyword>Hepatitis C</keyword>
</DOC>